Mural Oncology plc (NASDAQ:MURA – Get Free Report)’s stock price fell 1.9% during mid-day trading on Thursday . The stock traded as low as $3.44 and last traded at $3.53. 147,884 shares were traded during mid-day trading, a decline of 44% from the average session volume of 262,671 shares. The stock had previously closed at $3.60.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley began coverage on Mural Oncology in a report on Thursday, April 4th. They issued an “overweight” rating and a $13.00 price target on the stock.
Get Our Latest Analysis on MURA
Mural Oncology Stock Down 1.9 %
Mural Oncology (NASDAQ:MURA – Get Free Report) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($3.57) EPS for the quarter. On average, equities analysts forecast that Mural Oncology plc will post -10.63 earnings per share for the current fiscal year.
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Stories
- Five stocks we like better than Mural Oncology
- How Can Investors Benefit From After-Hours Trading
- Hasbro’s Management Made All the Right Calls This Quarter
- What is an Earnings Surprise?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- What are earnings reports?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
